PMID- 34712132
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211030
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and 
      Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal 
      Neovascularization: A Systematic Review and Meta-Analysis.
PG  - 696201
LID - 10.3389/fphar.2021.696201 [doi]
LID - 696201
AB  - Background: Conbercept is a new anti-vascular endothelial growth factor (VEGF) 
      drug. Here, we systematically conducted the efficacy, safety, compliance, and 
      pharmacoeconomic evaluation of intravitreal conbercept (IVC) compared with other 
      treatments in patients with neovascular age-related macular degeneration (nAMD), 
      diabetic macular edema (DME), or pathologic myopia choroidal neovascularization 
      (pmCNV). Methods: Databases of PubMed, Embase, Cochrane Library, 
      ClinicalTrials.gov, SinoMed, China National Knowledge Infrastructure, and WanFang 
      Data were systematically searched from the inception to July 27, 2021. Randomized 
      clinical trials and pharmacoeconomic studies comparing IVC with control groups in 
      adults with nAMD, DME, or pmCNV were reviewed and selected. Meta-analyses were 
      performed using the fixed-effects model when pooled data were homogeneous. 
      Heterogeneous data were analyzed using the random-effects model. Primary outcomes 
      included visual improvement rate, mean change in visual acuity or best corrected 
      visual acuity, and pharmacoeconomic outcomes. Additional outcomes were the mean 
      change in fundus examination values, adverse events (AEs), quality-of-life 
      measures, and number of injections. Results: Among 3,591 screened articles, 22 
      original studies with 1,910 eyes of patients were finally included. For nAMD and 
      DME, IVC was significantly associated with better visual acuity or best corrected 
      visual acuity improvement and fundus quantitative measures than placebo, laser 
      photocoagulation (LP), or intravitreal triamcinolone acetonide (IVT). However, 
      IVC showed non-inferior efficacy to intravitreal ranibizumab (IVR) according to 
      low quality of evidence, and there was lack of trials comparing the priority of 
      IVC to other anti-VEGF regimens. No definitive increased risk of ocular or 
      non-ocular AEs were observed in the study groups. All patients with AEs recovered 
      after symptomatic treatments, and no severe AEs occurred. Patients treated with 
      IVC might have higher quality-of-life scores than those in IVR in nAMD or LP in 
      DME. Additionally, IVC showed cost-utility advantages in nAMD and 
      cost-effectiveness advantages than IVR in pmCNV in China. Conclusion: IVC is 
      well-tolerated and effective for improving vision acuity and quantitative 
      measures in fundus condition in patients with nAMD and DME compared with LP, IVT, 
      and placebo, but gains comparable efficacy to IVR. However, well-designed, 
      large-sample, and long-term evaluation of IVC shall be conducted in additional 
      studies worldwide.
CI  - Copyright (c) 2021 Zhou, Zheng, Wang, Men and Zhai.
FAU - Zhou, Pengxiang
AU  - Zhou P
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 
      China.
FAU - Zheng, Siqian
AU  - Zheng S
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 
      China.
FAU - Wang, Ente
AU  - Wang E
AD  - Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, 
      Beijing, China.
FAU - Men, Peng
AU  - Men P
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
FAU - Zhai, Suodi
AU  - Zhai S
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211012
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8546330
OTO - NOTNLM
OT  - anti-VEGF
OT  - conbercept
OT  - diabetic macular edema
OT  - neovascular age-related macular degeneration
OT  - pathologic myopia choroidal neovascularization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/30 06:00
MHDA- 2021/10/30 06:01
PMCR- 2021/10/12
CRDT- 2021/10/29 06:24
PHST- 2021/04/19 00:00 [received]
PHST- 2021/08/10 00:00 [accepted]
PHST- 2021/10/29 06:24 [entrez]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2021/10/30 06:01 [medline]
PHST- 2021/10/12 00:00 [pmc-release]
AID - 696201 [pii]
AID - 10.3389/fphar.2021.696201 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Oct 12;12:696201. doi: 10.3389/fphar.2021.696201. 
      eCollection 2021.